---
document_datetime: 2023-09-21 18:18:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/cancidas-epar-all-authorised-presentations_en.pdf
document_name: cancidas-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9395939
conversion_datetime: 2025-12-15 19:45:30.333635
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name   | Strength   | Pharmaceutical Form                              | Route of Administration   | Immediate Packaging   | Package size   |
|------------------|-------------------|------------|--------------------------------------------------|---------------------------|-----------------------|----------------|
| EU/1/01/196/001  | Cancidas          | 50 mg      | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 1 vial         |
| EU/1/01/196/003  | Cancidas          | 70 mg      | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 1 vial         |